SU18. GLP-1 Receptor Agonist Treatment in Schizophrenia Patients With Obesity

Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are registered for treatment of both obesity and type 2 diabetes, and we investigated metabolic and cognitive effects of the GLP-1RA, exenatide once weekly, in nondiabetic, antipsychotic-treated, obese patients with schizophrenia. Meth...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Schizophr Bull
Main Authors: Ishøy, Pelle L., Knop, Filip K., Broberg, Brian V., Bak, Nikolaj, Andersen, Ulrik B., Jørgensen, Niklas R., Fagerlund, Birgitte, Holst, Jens J., Glenthøj, Birte Y., Ebdrup, Bjorn
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2017
Assuntos:
Abstracts
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5476046/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/schbul/sbx024.017
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares